Europe continues to lose ground in clinical trials

In a stark revelation, the European pharmaceutical industry has witnessed a significant decline in its share of global clinical trials. The latest data indicates that Europe now accounts for just 9% of all industry-sponsored clinical trials, a sharp drop from the 19% it held a decade ago. This trend is a cause for concern as it underscores the continent's dwindling competitiveness in a field that is essential for advancing medical research and healthcare.

The Shrinking Role of Europe in Clinical Trials

The European share of clinical trials has been on a downward trajectory for several years. According to recent reports, Europe's share has plummeted to 9%, a significant decline from the 19% it commanded ten years ago. This drop is not an isolated phenomenon; it reflects broader structural issues within the European pharmaceutical landscape.

Comparative Analysis

To put this decline into perspective, let's look at some key statistics. In 2020, Europe accounted for 19.3% of global clinical trials, a decrease of 6.3% compared to the previous decade. This decline is a stark contrast to the growth seen in other regions. For instance, Eastern European countries like Bulgaria, Croatia, and Hungary have seen their share of clinical trial patients rise from around 15% in 2006 to 18% by 2008.

The Rise of Other Regions

The shift away from Europe is not limited to clinical trials but also extends to research and development (R&D) investment and pharmaceutical manufacturing. The United States, in particular, has been at the forefront of this trend, with 47% of new drugs originating from the country compared to Europe's 23%. The US has also dominated Advanced Therapies Medicinal Products (ATMPs), with 50% of the world's ATMP manufacturing facilities located there.

Asia's Growing Influence

Asia is rapidly becoming a significant player in the clinical trials landscape. The region's share of clinical trial patients has increased, with Asia accounting for 7.2% of global recruitment in the period analyzed. The growth in Asia is attributed to several factors, including the establishment of numerous research centers and a more favorable regulatory environment.

Challenges Facing Europe

Several factors are contributing to Europe's decline in clinical trials. These include:

Policy and Regulatory Barriers

One of the primary issues is the regulatory environment. The European Union's pharmaceutical legislation is complex and often slow to adapt to new technologies and methods. This has led to a siloed approach to policymaking, where different regions and institutions operate in isolation rather than in a cohesive ecosystem.

Lack of Incentives

The reduction of incentives for R&D, such as those for orphan drugs and pediatric treatments, has also been a concern. These incentives have been crucial for launching innovation in specific areas, but their reduction has dampened the industry's enthusiasm for investing in research.

Digital Transformation

Another challenge is the lack of digital transformation within the European pharmaceutical industry. The need for a vibrant digital ecosystem is urgent, as it would enhance the efficiency of clinical trials and attract more investments. However, the current market dynamics and regulatory frameworks are not supportive of this transition.

Addressing the Decline

To reverse this trend, several steps need to be taken:

High-Level Forum

The European Commission has proposed a new Pharmaceutical Strategy aimed at boosting the continent's competitiveness in biopharmaceutical innovation. This strategy includes the creation of a High-Level Forum comprising authorities, the scientific community, patients, and industry stakeholders. The forum's goal is to define measures that will make Europe an attractive destination for biomedical research investments.

Regulatory Reforms

Regulatory reforms are essential to create a more conducive environment for clinical trials. This includes streamlining the approval process, reducing bureaucratic hurdles, and adopting flexible regulatory frameworks that support innovation. The EFPIA report emphasizes the need for policies that foster the growth of emerging ATMP clusters and provide support across the entire R&D, manufacturing, and clinical trial ecosystem.

Early Access Mechanisms

Supporting early access mechanisms, such as the generation and use of real-world evidence, is crucial. This approach allows for the conditional approval of medicines, enabling them to reach patients earlier while generating data that can influence future research investments. The Commission's proposals for revised pharmaceutical legislation should focus on supporting innovative trial designs and new methods of evidence generation and assessment.

Digital Capabilities

Boosting EU digital transformation is vital. Developing digital capabilities will enhance the efficiency of clinical trials, reduce administrative burdens, and improve transparency. This is essential for making Europe an attractive location for companies to locate their research, clinical trials, and manufacturing activities.

Conclusion

Europe's decline in clinical trials is a pressing issue that requires immediate attention. The continent's share of global clinical trials has plummeted to 9%, a stark contrast to its previous dominance. To regain its ground, Europe must address policy and regulatory barriers, provide adequate incentives for R&D, and invest in digital transformation. The proposed Pharmaceutical Strategy and regulatory reforms offer a starting point, but sustained efforts are needed to create a vibrant R&D ecosystem that attracts investments and supports innovation.

---

References

• Europe has the challenge of regaining ground lost to the US and Asia in drug research. Distefar. Retrieved from https://distefar.com/en/europe-has-the-challenge-of-regaining-ground-lost-to-the-us-and-asia-in-drug-research/
• France losing traction as European trial site. PharmaTimes. Retrieved from https://pharmatimes.com/news/france_losing_traction_as_european_trial_site_985724/
• Europe continues to lose ground in clinical trials. MedWatch. Retrieved from https://medwatch.com/News/regulation/article17561872.ece
• Europe's share of global medicines R&D shrinks by a quarter in 20 years as sector's declining trends continue. EFPIA. Retrieved from https://www.efpia.eu/news-events/the-efpia-view/efpia-news/europe-s-share-of-global-medicines-rd-shrinks-by-a-quarter-in-20-...